Your session is about to expire
← Back to Search
Binimetinib + Encorafenib for Solid Cancers (BEAVER Trial)
BEAVER Trial Summary
This trial is testing if two drugs can stop the growth of cancer in patients with class 2 or 3 BRAF mutations when no other standard therapy is available.
BEAVER Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowBEAVER Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 702 Patients • NCT02928224BEAVER Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You plan to start a new intense exercise routine after your first dose of the study medication.I am older than 18 years.You must be willing and able to follow the study's schedule for visits, treatment, lab tests, and other procedures.I have or am at risk for blocked blood vessels in my eye.I am willing and able to follow the study's requirements, including treatments and check-ups.I have had treatment for inflammatory bowel disease or Crohn's within the last year.My cancer has a specific BRAF gene change.My cancer is advanced, cannot be cured, and standard treatments have failed or are not suitable.I have a history of conditions that increase my risk of blood clots, not related to cancer.I agree to provide a tumor sample for testing before starting treatment.I have a muscle disorder that could increase my CK levels.The investigator thinks you have a health condition that could be risky for you if you participate in the clinical trial, or you might not be able to follow the study procedures properly.I have a history of pancreatitis.My tumor has the BRAF V600E mutation.I have been treated with BRAF or MEK inhibitors before.My cancer is advanced, cannot be cured, and standard treatments have failed or are not suitable.I am willing to provide tumor samples for the study.I am older than 18 years.I haven't had any other cancers in the last 3 years.I am a male and agree to use effective contraception and not donate sperm until 90 days after my last dose.I have HIV that is not currently managed with medication.I am able to understand and follow the study's requirements.My cancer has spread to the lining of my brain and spinal cord.I have a stomach or intestine problem that affects how I absorb medicine.I haven't had chemotherapy, immunotherapy, or targeted therapy in the last 4 weeks.I have brain metastasis causing symptoms.My cancer has a BRAF gene mutation.My melanoma has a BRAF V600K mutation.You have read and understood the information about the study and have agreed to participate.My organs are functioning well.I am a woman who can have children and my pregnancy test is negative.I had major surgery less than 3 weeks ago or am still dealing with its side effects.You should be able to swallow pills.You willingly agreed to participate in the study and signed a document confirming your decision.You have a condition that can be measured by a specific medical criteria called RECIST v1.1.You have been fully informed about the study and have agreed to participate.I am fully active and can carry on all my pre-disease activities without restriction.I have heart problems or significant heart disease.I can swallow pills.My condition matches the study's specific disease requirements.
- Group 1: Binimetinib + Encorafenib
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What safety protocols have been observed with Binimetinib treatments?
"There is some evidence of Binimetinib's safety, thus it has been assigned a score of 2 on the 1-3 scale. The Phase 2 designation means that there is no available data to demonstrate efficacy at this time."
Is this experimental research the inaugural venture of its kind?
"Binimetinib has been the object of research since 2011, when Pfizer sponsored its inaugural trial involving 183 patients. Since then, it recieved Phase 2 approval and there are currently 63 studies concerning Binimetinib occurring across 1256 cities in 41 countries."
Has there been any extant research on the use of Binimetinib?
"At the moment, 63 experiments related to Binimetinib are underway. 4 of them have advanced beyond Phase 3 clinical trials. While Orange City Florida has a disproportionately high concentration of studies on this drug, there are 3543 other locations running such tests globally."
What has Binimetinib been traditionally used to treat?
"Binimetinib has been approved as a therapeutic agent for metastatic melanoma and unresectable melanoma with the BRAF V600K mutation."
How many participants is the research team recruiting for this experiment?
"Affirmative. Clinicaltrials.gov states that the trial, which was posted on June 7th 2019, is recruiting patients for participation at a single medical site with a target of 26 participants."
Is enrollment currently available for this trial?
"Affirmative. The clinicaltrials.gov page displays that this medical project, which was originally posted on June 7th 2019, requires volunteers at the present moment. Around 26 individuals will be accepted at a single location for participation in the research study."
Share this study with friends
Copy Link
Messenger